"The U.S. Food and Drug Administration today approved Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF).
Idiopathic pulmonary fibrosis is a condition in which the lungs become progressively scarred o"...
The following adverse reactions are described in greater detail in other sections:
- Psychiatric Events Including Suicidality [see WARNINGS AND PRECAUTIONS]
- Weight Decrease [see WARNINGS AND PRECAUTIONS]
Adverse Reactions In Clinical Studies
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety data described below reflect exposure of 4438 patients to DALIRESP 500 mcg once daily in four 1year placebo-controlled trials, two 6-month placebo-controlled trials, and two 6-month drug add-on trials [see Clinical Studies]. In these trials, 3136 and 1232 COPD patients were exposed to DALIRESP 500 mcg once daily for 6 months and 1-year, respectively.
The population had a median age of 64 years (range 40-91), 73% were male, 92.9% were Caucasian, and had COPD with a mean pre-bronchodilator forced expiratory volume in one second (FEV1) of 8.9 to 89.1% predicted. In these trials, 68.5% of the patients treated with DALIRESP reported an adverse reaction compared with 65.3% treated with placebo.
The proportion of patients who discontinued treatment due to adverse reaction was 14.8% for DALIRESP-treated patients and 9.9% for placebo-treated patients. The most common adverse reactions that led to discontinuation of DALIRESP were diarrhea (2.4%) and nausea (1.6%).
Serious adverse reactions, whether considered drug-related or not by the investigators, which occurred more frequently in DALIRESP-treated patients include diarrhea, atrial fibrillation, lung cancer, prostate cancer, acute pancreatitis, and acute renal failure.
Table 1 summarizes the adverse reactions reported by ≥ 2% of patients in the DALIRESP group in 8 controlled COPD clinical trials.
Table 1: Adverse Reactions Reported by ≥ 2% of
Patients Treated with DALIRESP 500 mcg daily and Greater Than Placebo
|Diarrhea||420 (9.5)||113 (2.7)|
|Weight decreased||331 (7.5)||89 (2.1)|
|Nausea||209 (4.7)||60 (1.4)|
|Headache||195 (4.4)||87 (2.1)|
|Back pain||142 (3.2)||92 (2.2)|
|Influenza||124 (2.8)||112 (2.7)|
|Insomnia||105 (2.4)||41 (1.0)|
|Dizziness||92 (2.1)||45 (1.1)|
|Decreased appetite||91 (2.1)||15 (0.4)|
Adverse reactions that occurred in the DALIRESP group at a frequency of 1 to 2% where rates exceeded that in the placebo group include:
Musculoskeletal and connective tissue disorders -muscle spasms
Nervous system disorders -tremor
Psychiatric disorders -anxiety, depression
The following adverse reactions have been identified from spontaneous reports of DALIRESP received worldwide and have not been listed elsewhere. These adverse reactions have been chosen for inclusion due to a combination of seriousness, frequency of reporting or potential causal connection to DALIRESP. Because these adverse reactions were reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency or establish a causal relationship to DALIRESP exposure: hypersensitivity reactions (including angioedema, urticaria and rash), gynecomastia.
Read the Daliresp (roflumilast) Side Effects Center for a complete guide to possible side effects
Drugs That Induce Cytochrome P450 (CYP) Enzymes
Strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness of DALIRESP. Therefore the use of strong cytochrome P450 inducers (e.g., rifampicin, phenobarbital, carbamazepine, and phenytoin) with DALIRESP is not recommended [see Drug Interactions under PRECAUTIONS and CLINICAL PHARMACOLOGY].
Drugs That Inhibit Cytochrome P450 (CYP) Enzymes
The co-administration of DALIRESP (500 mcg) with CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) may increase roflumilast systemic exposure and may result in increased adverse reactions. The risk of such concurrent use should be weighed carefully against benefit [see CLINICAL PHARMACOLOGY].
Oral Contraceptives Containing Gestodene And Ethinyl Estradiol
The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. The risk of such concurrent use should be weighed carefully against benefit [see CLINICAL PHARMACOLOGY].
Read the Daliresp Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 12/7/2015
Additional Daliresp Information
Daliresp - User Reviews
Daliresp User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.